ARTICLE | Company News
ID Biomed to acquire Intellivax
March 27, 2001 8:00 AM UTC
ID Biomedical (IDBE; TSE:IDB) will acquire intranasal vaccines developer Intellivax for 4 million shares, or about $12.5 million using IDBE's Tuesday morning NASDAQ price of $3.125. Intellivax (Cote S...